Background
==========

Germline mutations in *BRCA1*and *BRCA2*genes predispose women to an increased risk of breast/ovarian cancer. Both genes have important roles in DNA damage repair and are implicated in gene expression regulation. We have previously shown that normal fibroblasts from mutation carriers can be distinguished from noncarriers following radiation-induced DNA damage. In this new study we used lymphocytes to determine whether these also show differential response to induced DNA damage and whether expression profiling using microarray technology could be used to accurately predict the *BRCA*genotype.

Methods
=======

Short-term lymphocyte cultures were established from fresh blood samples from 20 *BRCA1*and 20 *BRCA2*mutation carriers and from 10 negative controls (individuals tested negative for the mutation present in the family). Lymphocytes were subjected to 8 Gy ionizing irradiation to induce DNA damage and RNA was extracted 1 hour post γ-irradiation. For expression profiling, genome-wide (30 K) spotted cDNA microarrays manufactured by the Cancer Research UK Microarray Facility were used. We then applied the support vector machine (SVM) classifier with statistical feature selection to determine the best feature set for predicting *BRCA1*and *BRCA2*heterozygous genotypes. We also investigated the prediction accuracy using a nonprobabilistic classifier (SVM) and a probabilistic classifier (Gaussian process classifier).

Results and conclusion
======================

We achieved high accuracy (92% to 96%) in predicting the mutation carrier status. We shall present the detailed outcome of using the SVM classifier and the Gaussian process classifier in the task of distinguishing between the three classes, *BRCA1*and *BRCA2*mutation carriers and noncarriers, and evaluate whether this microarray technology can be used to facilitate the clinical detection and classification of mutations.
